Incidencia de toxicidad cardiaca en pacientes adultos con tratamiento con antraciclinas en el Hospital Oncológico SOLCA de Loja durante el periodo de 2010 a 2012

Abstract

Abstract : The results of echocardiograms of 50 patients treated with anthracyclines in the period 2010 to 2012 were analyzed. Of the patients treated none presented cardiac toxicity, even those that exceeded the accumulated dose to develop the mentioned alteration. There was no evidence that the administration of Doxorubicin at doses greater than 300 mg / m2 concomitantly with Trastuzumab increased the risk of cardiotoxicity. Conclusion: The data obtained from the patients who received anthracyclines were not conclusive to affirm or deny that they developed cardiotoxicity, some did not have the accumulated dose to develop the alteration and those who exceeded the recommended dose did not present evidence of cardiac alteration. For obvious reasons, it did not influence the interaction with Trastuzumab, or risk factors such as age or previous cardiac pathologies.